This Friday! How to Calculate Comms/IR Risk
|
Hi! Many of the decisions we’re asked to make have no clear or obvious correct answer. Taking a public position on an issue may reassure employees, but create political or commercial exposure. Staying silent may protect the company legally but undermine trust with patients or other stakeholders. And sometimes, the pressure to respond quickly doesn't leave much room to think through the longer-term implications. At this Friday's Comm Convo, we'll explore how communicators can help leadership make tough calls, especially during moments when legal, policy, commercial, and employee considerations all pull in a different direction. October Comm Convo: The Comms Risk Recalculation📅 Friday, October 30th @ 12-1 p.m. ET / 9-10 a.m. PT / 16:00-17:00 GMT Free for T2B Pro and Student members / $40 for Basic members Featured speakers:💬 Chrissy Trank, Senior Director, Oncology Drug Development Communications, Bristol Myers Squibb 💬 Ethan Lovell, Senior Director of IR, formerly Avidity Biosciences 💬 Lisa Popyk, Communications Strategy Consultant, Writing Unlimited (Moderator) We'll discuss:
See you Friday! Lynnea P.S. - Before our Comm Convo on Friday, our Patient Advocacy & Engagement Roundtable is hosting on Thursday a candid, myth-busting discussion on patient advocacy assumptions for communicators. Join us! |
T2B Monthly
Hi! We're headed back to London next month for the Jefferies Healthcare Conference and London Life Sciences Week! With an increasingly international audience gathering for the conference, we're looking forward to bringing together more of our global T2B community through two events focused on giving back and connecting with fellow biopharma communicators. Even if you're not making the trip, we'd love your help spreading the word! Please share these invitations with UK-based colleagues,...
Hi! China's role in global biopharma has changed dramatically over the past few years, evolving from a lower-cost manufacturing and research hub into a major source of innovation, drug development, and licensing activity. At the same time, geopolitical tensions and shifting U.S. policies have raised questions about cross-border partnerships, investment, intellectual property, and supply chains. At our upcoming Media Minds Roundtable press panel, we'll hear from Drew Armstrong (Endpoints) and...
Hi! Patient advocacy is often most visible through awareness campaigns, community events, fundraising walks, and patient stories. But that’s of course only part of the picture, and for communicators, PA&E may be part of our own remit or something we engage with across the organization. At our next Patient Advocacy & Engagement Roundtable event, we’re turning the conversation over to the Roundtable members themselves for a candid, myth-busting discussion about what PA&E does, where it...